Powerful partnerships help drive our research for the greater good
The Institute for Glycomics has a broad portfolio of technologies and services available to industry, investors and academic organisations. It has a management framework and expert personnel in place to meet industry demands and has successfully co-developed products using its translational capability and specialised facilities from concept to market.
Novel therapeutics for hand, foot & mouth disease
Disruptive peptide anti-cancer drug candidates
Synthetic heparin mimetics
Novel vaccine approach for preventing Babesiosis
Development of a clinical phase malaria vaccine
Novel therapeutics to treat group A strep
A novel treatment for gonorrhoea in females
Gonococcal vaccine portfolio
Australian Centre for Cancer Glycomics (A2CG)
Label-free detection technology
Sulfated polysaccharides for wound management
The Institute for Glycomics has a portfolio of discovery to Phase 1 technologies and novel technology platforms available for licensing and co-development. It has successfully co-developed several of its drug and vaccine assets from preclinical stage to Phase 2 human clinical trials through industry partnerships.
The Institute has a suite of technology packages available for immediate investment. The Institute is experienced in negotiating and managing a range of investment types.
New drug to fight human parainfluenza virus
Griffith University's Institute for Glycomics and China Grand Pharma sign landmark deal to develop new drug for parainfluenza virus (hPIV)
Promising Phase 2 human clinical trial results
Institute for Glycomics and Melbourne-based company Paradigm Biopharmaceuticals Limited have reported impressive results from their Phase 2A clinical trials of a new drug candidate to treat viral arthritis.
Mushroom extracts could offer an immune cell boost
Research conducted by the Institute for Glycomics and Integria Healthcare has found that a combination of mushroom extracts is able to help boost the immune system.
World’s largest commercial glycan array launched
The Institute for Glycomics has partnered with Dextra Laboratories to launch the world’s largest commercial glycan array and bioanalytical service offering.
Ross River virus battle breakthrough
Research conducted by Griffith and Paradigm Biopharmaceuticals has uncovered a potential new treatment in the battle against alphavirus infections.
Strep A vaccine partnership raises hope
Griffith's Institute for Glycomics has partnered with Chinese pharmaceutical Olymvax Biopharmaceuticals Inc. for a new needle-free vaccine targeted at Streptococcus A infections, the cause of strep throat and rheumatic heart disease.
Curbing the impact of sepsis and septic shock
The Institute for Glycomics partners with Sirtex Pty Ltd to develop an anti-sepsis drug candidate.